Nyaradzo M Mgodi

Datos Biográficos

ID	7561683
NOMBRE	Nyaradzo M Mgodi
NOMBRES	Nyaradzo M
APELLIDO	Mgodi
FIRMA	MGODI N M
AFILIACIONES	University of Zimbabwe
ORCID	0000-0002-3085-5259
VERIFICADO	Sí
TOTAL DE OBRAS	25
TOTAL DE CITAS	0
TOTAL COMO AUTOR	25
TOTAL COMO EDITOR	0
PRIMER AÑO DE PUBLICACIÓN	2015
AÑO MÁS RECIENTE DE PUBLICACIÓN	2026
ÍNDICE H	0

A Systematic Review of Barriers and Facilitators to the Uptake and Adherence of Injectable PrEP Among Adolescent Girls and Young Women in Sub-Saharan Africa
Open AccessNoah Mancuso, Stacy Endres-Dighe et al.ARTICLEAIDS and Behavior2026
Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa
Open AccessKudzai Hlahla, Rahul Paul Choudhury et al.ARTICLEPLOS Global Public Health2025
Adolescent girls and young women (AGYW) in sub-Saharan Africa are at substantial risk of HIV acquisition and could benefit from oral pre-exposure prophylaxis (PrEP) for HIV prevention. Substance use may result in poor adherence, diminishing PrEP effectiveness. The effects of substance use on PrEP adherence in AGYW within the African context have not been extensively studied. We sought to determine the prevalence of substance use and its associati…
“…This could be a noble idea and a game changer.” The potential of a dual prevention pill for HIV and pregnancy prevention among adolescent girls and young women in Zimbabwe
Open AccessAdlight Dandadzi, S Mathur et al.ARTICLEPLOS Global Public Health2025
Adolescent girls and young women (AGYW) in Zimbabwe bear a double burden of HIV and unmet need despite the progress made in provision of family planning and oral pre-exposure prophylaxis (PrEP). We elicited opinions from AGYW and health care providers (HCPs) about a dual prevention pill (DPP) in development that combines oral contraceptives (OCs) with oral PrEP to simultaneously prevent unintended pregnancy and HIV, and potentially increase uptak…
Engagement of adolescent girls and young women into an early oral PrEP open-label study in Southern Africa
Open AccessMiliswa Magongo, Nomsa Mhlanga et al.ARTICLEBMC Public Health2025
ClinicalTrials.gov NCT02732730, 13 November 2018
A Dual Prevention Pill for HIV & Pregnancy Prevention
Open AccessNyaradzo M Mgodi, J Brady Burnett-Zieman et al.ARTICLEAIDS and Behavior2025
Adolescent girls and young women (AGYW) in sub-Saharan Africa are at risk for HIV/unintended pregnancy. Adherence and continuation to effective oral pre-exposure prophylaxis (PrEP) are limited in AGYW. We hypothesized that an over-encapsulated dual prevention pill (DPP) combining PrEP + oral contraceptive (OC) would be preferred, acceptable, and improve adherence compared to PrEP alone. We randomized HIV-uninfected, 16-24 year-olds 1:1 to use DPP…
“We chose PrEP because I wanted to be sure that this child my wife was going to conceive was indeed mine.” Factors influencing the choice of safer conception methods and experiences with its use
Open AccessJoelle Brown, Joelle M Brown et al.ARTICLEBMC Public Health2024
The differences in method preferences and experiences voiced by participants in this study and in other studies from the region point to the importance of having a variety of safer conception options in the service delivery package and addressing concerns about paternity, intimacy, and method-related attributes to enable HIV sero-discordant couples to safely achieve their reproductive goals
Perception of couples’ on multipurpose prevention technology attribute choice
Open AccessAdlight Dandadzi, Alinda M Young et al.ARTICLEBMC Public Health2024
Addressing the myths and misconceptions surrounding the use of contraceptives is crucial in promoting their acceptance and ultimate use. Strategies for addressing the drawbacks women might experience while using a particular product should be in place as new MPTs progress through the development pipeline and approach roll-out
Preventing HIV and achieving pregnancy among HIV sero-different couples
Open AccessJoelle Brown, Serah Gitome et al.ARTICLEPLOS Global Public Health2023
Safer conception services are needed to minimize HIV transmission among HIV sero-different couples desiring pregnancy. Few studies have evaluated the choices couples make when offered multiple safer conception methods or real-world method acceptability and effectiveness. We piloted a comprehensive safer conception program ( Clintrials . gov identifier: NCT03049176) for HIV sero-different couples planning pregnancy in Zimbabwe to measure feasibili…
The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study
Open AccessGeetha Beauchamp, Sybil Hosek et al.ARTICLEAIDS and Behavior2023
To develop effective PrEP adherence interventions, it is important to understand the interplay between disclosure of pre-exposure prophalxis (PrEP) use, social support, and PrEP adherence. We leveraged the HPTN 082 study conducted among 451 adolescent girls and young women (AGYW) (ages 16 to 25 years, 2016 to 2019) in South Africa and Zimbabwe. Among the 349 who had month three disclosure and PrEP adherence data, 60% (n = 206) felt supported by a…
Understanding the role of men in women's use of the vaginal ring and oral PrEP during pregnancy and breastfeeding
Petina Musara, Miriam Hartmann et al.ARTICLEAfrican Journal of AIDS Research2022
We examined men's influence on women's interest in biomedical HIV prevention during pregnancy and breastfeeding through structured questionnaires and focus group discussions with currently or recently pregnant and breastfeeding (P/BF) women ( n = 65), men with P/BF partners ( n = 63) and mothers/mothers-in-law of P/BF women ( n = 68) in eastern and southern Africa. Data were transcribed, coded and summarised into analytical memos. Men were depict…
Couples’ Preferences for “2 in 1” Multipurpose Prevention Technologies to Prevent Both HIV and Pregnancy
Open AccessAlexandra M Minnis, Juliane Etima et al.ARTICLEAIDS and Behavior2022
Couples’ decision making regarding the use of multipurpose prevention technology (MPT) for pregnancy and HIV prevention
Open AccessMarie C D Stoner, Erica N Browne et al.ARTICLEAIDS and Behavior2022
Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial
Open AccessBrenda Gati Mirembe, Maria Valdez Cabrera et al.ARTICLEAIDS and Behavior2022
Women’s experience receiving drug feedback and adherence counseling in MTN-025/Hope - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring
Open AccessAriana Katz, Iván C Balán et al.ARTICLEAIDS and Behavior2022
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
Open AccessAshley Mayo, Erica N Browne et al.ARTICLEAIDS and Behavior2021
We evaluated the acceptability of the 25 mg dapivirine vaginal ring (DVR) as an HIV prevention intervention and its influence on DVR adherence in the MTN-020/ASPIRE phase III trial. Acceptability measures were captured using ACASI at month 3 and end of product use (median 24 months, IQR 15-30). Monthly returned rings were classified as nonadherent if dapivirine release rate was ≤ 0.9 mg/month. Associations between acceptability measures and nonad…
The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence
Open AccessMarie C D Stoner, Elizabeth R Brown et al.ARTICLEAIDS and Behavior2021
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082
Open AccessJennifer Velloza, Nomhle Khoza et al.ARTICLEJournal of the International AIDS…2020
Implementation of a fidelity monitoring process to assess delivery of an evidence-based adherence counseling intervention in a multi-site biomedical HIV prevention study
Iván C Balán, Cody Lentz et al.ARTICLEAIDS Care2020
Pre-Exposure Prophylaxis (PrEP) trials often implement counseling to support product adherence. Counseling fidelity can vary significantly across providers and time. Fidelity monitoring can ensure that counseling is delivered as designed. We describe the process, feasibility, and outcomes of monitoring Options counseling fidelity in an open-label study of the dapivirine vaginal ring MTN-025/HOPE. After initial training, 63 counselors from 14 site…
Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe
Open AccessPetina Musara, Cecilia Milford et al.ARTICLEAIDS and Behavior2020
Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The Hope Study)
Open AccessIván C Balán, Rebecca Giguere et al.ARTICLEAIDS and Behavior2020
Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms
Open Accesson behalf of the Quatro Study Team, Rachel Weinrib et al.ARTICLEAIDS and Behavior2019
How well a product fit in with participants' lifestyles was important to their overall satisfaction. For on-demand products, greater flexibility around timing of use was desired, to avoid coital dependency of the dosing
Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa
Miria Chitukuta, Zoe Duby et al.ARTICLECulture Health & Sexuality2019
Rumours may influence health-related behaviours, including the uptake of and adherence to HIV prevention products. This study assessed the safety and effectiveness of a vaginal ring delivering the antiretroviral dapivirine for HIV prevention in Africa. We explored negative rumours about study participation and the vaginal ring amongst study participants and their communities in Malawi, Uganda, South Africa and Zimbabwe. In total 214 women partici…
How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe
Open AccessPetina Musara, Elizabeth Montgomery et al.ARTICLEAIDS and Behavior2017
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Jared M Baeten, Thesla Palanee‐phillip et al.ARTICLENew England Journal of Medicine2016
BACKGROUND: Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence. Longer-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medications and provide HIV-1 protection. METHODS: We conducted a ph…
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne Marrazzo, Jeanne M Marrazzo et al.ARTICLENew England Journal of Medicine2015
BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimb…